thalidomide has been researched along with zoledronic acid in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (50.00) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Hussein, MA; Juturi, JV; Lieberman, I | 1 |
| Dolan, G; Jones, SG; Lengyel, K; Myers, B | 1 |
| Avcu, F; Nevruz, O; Pekel, A; Sengul, A; Ural, AU; Yalcin, A; Yilmaz, MI; Zerman, M | 1 |
| Rajkumar, SV | 1 |
| Chou, T | 1 |
| Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E | 1 |
| Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E | 1 |
| Do, KA; Jonasch, E; Lin, P; Lin, SH; Mathew, P; Pagliaro, LC; Rhines, L; Siefker-Radtke, A; Tannir, N; Tibbs, R; Tu, SM | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Baccarani, M; Brioli, A; Cangini, D; Catalano, L; Cavo, M; Ceccolini, M; Cellini, C; D'Arco, A; Di Raimondo, F; Offidani, M; Perrone, G; Ronconi, S; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E | 1 |
| Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND | 1 |
| Bilic, S; Copeman, M; Cremers, S; Kennedy, N; Lynch, K; Neeman, T; Ravera, C; Roberts, A; Schran, H; Spencer, A | 1 |
| Adam, Z; Krejcí, M; Krikavová, L; Mechl, M; Moulis, M; Navrátil, M; Neumann, C; Pour, L; Vanícek, J; Veselý, K; Vorlícek, J | 1 |
| Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E | 1 |
| Arima, S; Hayakawa, K; Hoshinaga, K; Kusaka, M; Maruyama, T; Miyakawa, S; Mori, S; Sasaki, H; Shiroki, R | 1 |
| Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT | 1 |
| Gnanapandithan, K; Kumar, S; Malhotra, P; Sharma, A; Singh, S; Varma, S | 1 |
| Chen, Y; Kim, K; Kim, YK; Pai, VR; Srivastava, A; Suh, C; Teoh, G; Yoon, SS | 1 |
| Iida, S | 1 |
| Ashcroft, AJ; Bell, SE; Child, JA; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Szubert, AJ | 1 |
| Dispenzieri, A; Gertz, MA; Greipp, PR; Hassoun, H; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, KM; Lust, JA; Mandrekar, SJ; Rajkumar, SV; Reeder, CB; Roy, V; Witzig, TE | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Suzuki, K | 1 |
| McCarthy, PL | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
| Dong, W; Liu, J; Qi, M; Song, Z; Sun, H; Yin, L | 1 |
| Abe, M; Aihara, K; Amachi, R; Bat-Erdene, A; Cui, Q; Endo, I; Fujii, S; Harada, T; Iwasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Sogabe, K; Teramachi, J; Yoshida, S | 1 |
| Li, Z; Mao, T; Sheng, J; Xu, L; Yu, Y | 1 |
| Bell, SE; Cairns, DA; Child, JA; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Royle, KL | 1 |
| Dalgleish, AG; Kasow, S; Samad, M; Smith, PL; Yogaratnam, Y | 1 |
| Kasinathan, G | 1 |
9 review(s) available for thalidomide and zoledronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Multiple myeloma: present and future.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Oxides; Pamidronate; Thalidomide; Zoledronic Acid | 2002 |
Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Life Tables; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome; Zoledronic Acid | 2003 |
[Multiple myeloma--recent advances in diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid | 2005 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid | 2013 |
Use of zoledronic acid combined with thalidomide in the treatment of Gorham-Stout disease.
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Follow-Up Studies; Humans; Imidazoles; Immunosuppressive Agents; Male; Osteolysis, Essential; Thalidomide; Tomography, X-Ray Computed; Zoledronic Acid | 2018 |
9 trial(s) available for thalidomide and zoledronic acid
| Article | Year |
|---|---|
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Collagen Type I; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Pain; Peptides; Thalidomide; Treatment Outcome; Zoledronic Acid | 2006 |
Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prognosis; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Zoledronic Acid | 2003 |
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Interferon-gamma; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Thalidomide; Zoledronic Acid | 2006 |
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Thalidomide; Zoledronic Acid | 2006 |
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Diphosphonates; Female; Humans; Imidazoles; Kidney; Male; Middle Aged; Multiple Myeloma; Prednisolone; Thalidomide; Zoledronic Acid | 2008 |
Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Models, Biological; Multiple Myeloma; Thalidomide; Treatment Outcome; Zoledronic Acid | 2012 |
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Thalidomide; Zoledronic Acid | 2012 |
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clodronic Acid; Consolidation Chemotherapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Quality of Life; Remission Induction; Self Report; Surveys and Questionnaires; Thalidomide; Transplantation, Autologous; Young Adult; Zoledronic Acid | 2018 |
16 other study(ies) available for thalidomide and zoledronic acid
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.
Topics: Aged; Creatinine; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Immunosuppressive Agents; Male; Multiple Myeloma; Thalidomide; Zoledronic Acid | 2002 |
The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Cycle; Cell Division; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Egtazic Acid; Enzyme Inhibitors; Humans; Imidazoles; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasm Proteins; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Protein Kinase C; Staurosporine; Thalidomide; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous; Zoledronic Acid | 2007 |
[Treatment of multiple angiomatosis involving the skeleton and the abdominal and thoracic cavities with interferon alpha, thalidomide and zoledronate].
Topics: Adult; Angiogenesis Inhibitors; Angiomatosis; Diagnosis, Differential; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Interferon-alpha; Male; Mediastinal Diseases; Peritoneal Diseases; Spinal Diseases; Thalidomide; Zoledronic Acid | 2008 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid | 2009 |
[Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Carcinoma, Renal Cell; Chronic Disease; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Infusions, Intravenous; Interleukin-2; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Renal Dialysis; Thalidomide; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Necrosis; Osteoclasts; Osteonecrosis; Thalidomide; Zoledronic Acid | 2009 |
Development of multiple myeloma in a case of longstanding ankylosing spondylitis: more than a coincidence?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphosphonates; Etoricoxib; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pyridines; Sacroiliitis; Spondylitis, Ankylosing; Sulfones; Thalidomide; Zoledronic Acid | 2011 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
[Effect of thalidomide on development of bisphosphonate-related osteonecrosis of the jaws in rats].
Topics: Animals; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Diphosphonates; Disease Models, Animal; Imidazoles; Molar; Neovascularization, Physiologic; Rats; Thalidomide; Tooth Extraction; Zoledronic Acid | 2015 |
Expansion of Th
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Th1 Cells; Thalidomide; Zoledronic Acid | 2017 |
Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Deoxycytidine; Drug Interactions; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Interferon-gamma; Lymphocyte Activation; Oxaliplatin; Pancreatic Neoplasms; Thalidomide; Zoledronic Acid | 2021 |
Primary plasma cell leukaemia in a 39-year-old man.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Bortezomib; Dexamethasone; Diagnosis, Differential; Drug Therapy, Combination; Humans; Immunoglobulin G; Immunoglobulin lambda-Chains; Immunosuppressive Agents; Leukemia, Plasma Cell; Male; Thalidomide; Zoledronic Acid | 2020 |